|Table of Contents|

Research status and prospects of immune checkpoint inhibitors in the treatment of bladder cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 04
Page:
763-769
Research Field:
Publishing date:

Info

Title:
Research status and prospects of immune checkpoint inhibitors in the treatment of bladder cancer
Author(s):
YANG Tianjun; PANG Lei; WEN Xiaodong
Department of Urology,the Fifth Hospital of Shanxi Medical University,Shanxi Taiyuan 030001,China.
Keywords:
bladder cancer; immunotherapy; immune checkpoint inhibitors(ICI); muscular invasive bladder cancer
PACS:
R737.14
DOI:
10.3969/j.issn.1672-4992.2023.04.033
Abstract:
In recent years,the rapid development of immunotherapy has changed the pattern of tumor therapy and become a new anti-tumor method after surgery,radiotherapy and chemotherapy.As the most widely studied and effective immunotherapy at present,ICI have shown good anti-tumor activity and safety in the treatment of bladder cancer.With the continuous development of clinical trials,immune checkpoint inhibitors(ICI)show great therapeutic potential in second-line or first-line treatment of advanced or metastatic bladder cancer,neoadjuvant and adjuvant therapy of muscular invasive bladder cancer,high-risk non-muscular invasive bladder and bladder preservation therapy of muscle invasive bladder cancer.This article briefly reviews the progress of ICI in different stages of bladder cancer.

References:

［1］ SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71:209-249.
［2］ WITJES JA,BRUINS HM,CATHOMAS R,et al.European association of urology guidelines on muscle-invasive and metastatic bladder cancer:Summary of the 2020 guidelines［J］.Eur Urol,2021,79:82-104.
［3］ CAMBIER S,SYLVESTER RJ,COLLETTE L,et al.EORTC nomograms and risk groups for predicting recurrence,progression,and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus calmette-guérin［J］.Eur Urol,2016,69(1):60-69.
［4］ SANLI O,DOBRUCH J,KNOWLES MA,et al.Bladder cancer［J］.Nat Rev Dis Primers,2017,3:1-19.
［5］ TIAN Z,CAO S,LI C,et al.LncRNA PVT1 regulates growth,migration,and invasion of bladder cancer by miR-31/CDK1［J］.J Cell Physiol,2019,234(4):4799-4811.
［6］ 崔迎春,李建全,张典.肿瘤的免疫治疗［J/OL］.中国免疫学杂志:1-12［2022-05-08］.http://kns.cnki.net/kcms/detail/22.1126.R.20210730.1013.002.html.doi:10.3969/j.issn.1000-484X.2022.14.022. CUI YC,LI JQ,ZHANG D.Immunotherapy of tumor［J/OL］.Chinese Journal of Immunology:1-12［2022-05-08］.http://kns.cnki.net/kcms/detail/22.1126.R.20210730.1013.002.html.doi:10.3969/j.issn.1000-484X.2022.14.022.
［7］WILLSMORE ZN,COUMBE BGT,CRESCIOLI S,et al.Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade:Treatment of melanoma andanti-CTLA-4 checkpoint blockade:Treatment of melanoma and immune mechanisms of action［J］.Eur J Immunol,2021,51(3):544-556.
［8］ BELLMUNT J,DE WIT R,VAUGHN DJ,et al.Pembrolizumab as second-line therapy for advanced urothelial carcinoma［J］.N Engl J Med,2017,376(11):1015-1026.
［9］ BELLMUNT J,NECCHI A,DE WIT R,et al.Pembrolizumab(pembro)versus investigator's choice of paclitaxel,docetaxel,or vinflunine in recurrent,advanced urothelial cancer(UC):5-year follow-up from the phase 3 KEYNOTE-045 trial［J］.J Clin Oncol,2021,39(15):4532-4532.
［10］ POWLES T,DURAN I,VAN DER HEIJDEN MS,et al.Atezolizumab versus chemotherapy in patients with platinum-treated locally advancedor metastatic urothelial carcinoma(IMvigor211):A multicentre,open-label,phase 3 randomised controlled trial［J］.Lancet,2018,391(10122):748-757.
［11］ VAN DER HEIJDEN MS,LORIOT Y,DURAN I,et al.Atezolizumab(atezo)vs chemotherapy(chemo)in patients(pts)with platinum-treated locally advanced or metastatic urothelial carcinoma(mUC):A long-term overall survival(OS)and safety update from the phase III IMvigor211 study［J］.Annals of Oncology,2019,30:365-366.
［12］ STERNBERG CN,LORIOT Y,JAMES N,et al.Primary results from SAUL,a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract［J］.Eur Urol,2019,76(1):73-81.
［13］ SHARMA P,RETZ M,SIEFKER-RADTKE A,et al.Nivolumab in metastatic urothelial carcinoma after platinum therapy(CheckMate 275):A multicentre,single-arm,phase 2 trial［J］.Lancet Oncol,2017,18(3):312-322.
［14］ P SHARMA,BARON A,NECCHI A,et al.Abstract CT178:Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma:Efficacy and safety update and association between biomarkers and overall survival in Check Mate 275［J］.Cancer Res,2018,78(13):178.
［15］ POWLES T,O' DONNELL PH,MASSARD C,et al.Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma:Updated results from a phase 1/2 open-label study［J］.JAMA Oncol,2017,3(9):2411.
［16］ PATEL MR,ELLERTON J,INFANTE JR,et al.Avelumab in metastatic urothelial carcinoma after platinum failure(JAVELIN Solid Tumor):Pooled results from two expansion cohorts of an open-label,phase 1 trial［J］.Lancet Oncol,2018,19(1):51-64.
［17］ YE D,LIU J,ZHOU A,et al.Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma［J］.Cancer Sci,2021,112(1):305-313.
［18］ SHARMA P,SIEFKER-RADTKE A,DE BRAUD F,et al.Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma:CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results［J］.J Clin Oncol,2019,37(19):1608-1616.
［19］ MCGREGOR BA,ORCID ID,CAMPBELL MT,et al.Results of a multicenter,phase 2 study of nivolumab and ipilimumab for patientswith advanced rare genitourinary malignancies［J］.Cancer,2021,127(6):840-849.
［20］ BALAR AV,CASTELLANO D,O' DONNELL PH,et al.First-line pembrolizumab in cisplatin-ineligible patients with locally advanced andunresectable or metastatic urothelial cancer(KEYNOTE-052):A multicentre,single-arm,phase 2 study［J］.Lancet Oncol,2017,18(11):1483-1492.
［21］ O'DONNELL PH,BALAR AV,VUKY J,et al.First-line pembrolizumab(pembro)in cisplatin-ineligible patients with advanced urothelial cancer(UC):Response and survival results up to five years from the KEYNOTE-052 phase 2 study［J］.J Clin Oncol,2021,39(15):4508.
［22］ BALAR AV,GALSKY MD,ROSENBERG JE,et al.Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma:A single-arm,multicentre,phase 2 trial［J］.Lancet,2017,389(10064):67-76.
［23］ NECCHI A,JOSEPH RW,LORIOT Y,et al.Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma:Post-progression outcomes from the phase II IMvigor210 study［J］.Ann Oncol,2017,28(12):3044-3050.
［24］ POWLES T,CSOSZI T,OZGUROGLU M,et al.Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma(KEYNOTE-361):A randomised,open-label,phase 3 trial［J］.Lancet Oncol,2021,22(7):931-945.
［25］ LORIOT Y,ALVA AS,CSOSZI T,et al.Post-hoc analysis of long-term outcomes in patients with CR,PR,or SD to pembrolizumab or platinum-based chemotherapy(chemo)as IL therapy for advanced urothelial carcinoma in KEYNOTE-361［J］.Oncology 2021,39(6),435-435.
［26］ GALSKY MD,ARIJA JAA,BAMIAS A,et al.Atezolizumab with or without chemotherapy in metastatic urothelial cancer(IMvigor130):A multicentre,randomised,placebo-controlled phase 3 trial［J］.Lancet,2020,395(10236):1547-1557.
［27］ GOURD E.EMA restricts use of anti-PD-1 drugs for bladder cancer［J］.Lancet Oncol,2018,19(7):341.
［28］ KOYAMA S,AKBAY EA,LI YY,et al.Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints［J］.Nat Commun,2016,7:1-9.
［29］ POWLES T,VAN DER HEIJDEN MS,CASTELLANO D,et al.Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable,locally advanced or metastatic urothelial carcinoma(DANUBE):A randomised,open-label,multicentre,phase 3 trial［J］.Lancet Oncol,2020,21(12):1574-1588.
［30］ HERBST RS,ARKENAU HT,SANTANA-DAVILA R,et al.Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer,gastro-oesophageal cancer,or urothelial carcinomas(JVDF):A multicohort,non-randomised,open-label,phase 1a/b trial［J］.Lancet Oncol,2019,20(8):1109-1123.
［31］ ROSENBERG JE,GAJATE P,MORALES-BARRERA R,et al.Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase I b/U study(FORT-2)of first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression［J］.J Clin Oncol,2020,38(15):5014.
［32］ ROSENBERG JE,FLAIG TW,FRIEDLANDER TW,et al.Study EV-103:Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma［J］.J Clin Oncol,2020,38:441.
［33］ LEE JE,CHUNG CU.Update on the evidence regarding maintenance therapy［J］.Tuberc Respir Dis(Seoul),2014,76(1):1-7.
［34］ POWLES T,PARK SH,VOOG E,et al.Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma［J］.N Engl J Med,2020,383(13):1218-1230.
［35］ VADDEPALLY RK,KHAREL P,PANDEY R,et al.Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence［J］.Cancers(Basel),2020,12(3):738.
［36］ GALSKY MD,MORTAZAVI A,MILOWSKY MI,et al.Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer［J］.J Clin Oncol,2020,38(16):1797-1806.
［37］ NECCHI A,ANICHINI A,RAGGI D,et al.Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma(PURE-01):An open-label,single-arm,phase II study［J］.J Clin Oncol,2018,36(34):3353-3360.
［38］ BANDINI M,GIBB EA,GALLINA A,et al.Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy?First survival outcomes from the PURE-01 study［J］.Ann Oncol,2020,31(12):1755-1763.
［39］ POWLES T,KOCKX M,RODRIGUEZ-VIDA A,et al.Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial［J］.Nat Med,2019,25(11):1706-1714.
［40］ SZABADOS B,RODRIGUEZ-VIDA A,DURAN I,et al.Toxicity and surgical complication rates of neoadjuvant atezolizumab in patients with muscle-invasive bladder cancer undergoing radical cystectomy:Updated safety results from the ABACUS trial［J］.Eur Urol Oncol,2021,4(3):456-463.
［41］ ROSE TL,HARRISON MR,DEAL AM,et al.Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer［J］.J Clin Oncol,2021,39(28):3140-3148.
［42］ VAN DIJK N,GIL-JIMENEZ A,SILINA K,et al.Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer:The NABUCCO trial［J］.Nat Med,2020,26(12):1839-1844.
［43］ GAO J,NAVAI N,ALHALABI O,et al.Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma［J］.Nat Med,2020,26(12):1845-1851.
［44］ BAIORIN DF,WITJES JA,GSCHWEND JE,et al.Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma［J］.N Engl J Med,2021,384(22):2102-2114.
［45］ WITJES JA,GALSKY MD,GSCHWEND JE,et al.Health-related quality of life with adjuvant nivolumab after radical resection for high-risk muscle-invasive urothelial carcinoma:Results from the phase 3 CheckMate 274 trial［J/OL］.Eur Urol Oncol,2022,(22):28［2022-4-17］.https://www.sciencedirect.com/science/article/pii/S2588931122000281.doi:https://doi.org/10.1016/j.euo.2022.02.003.
［46］ POWLES T,BELLMUNT J,COMPERAT E,et al.Bladder cancer:ESMO clinical practice guideline for diagnosis,treatment and follow-up［J］.Ann Oncol,2022,33(3):244-258.
［47］ BELLMUNT J,HUSSAIN M,GSCHWEND JE,et al.Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma(IMvigor010):A multicentre,open-label,randomised,phase 3 trial［J］.Lancet Oncol,2021,22(4):525-537. ［48］ STEIN JP,LIESKOVSKY G,COTE R,et al.Radical cystectomy in the treatment of invasive bladder cancer:Long-term results in 1,054 patients［J］.J Clin Oncol,2001,19(3):666-675. ［49］ KRETSCHMER A,GRIMM T,BUCHNER A,et al.Midterm health-related quality of life after radical cystectomy:A propensity score-matched analysis［J］.Eur Urol Focus,2020,6(4):704-710. ［50］ TWYMAN-SAINT VC,RECH AJ,MAITY A,et al.Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer［J］.Nature,2015,520(7547):373-377. ［51］ DOVEDI SJ,ADLARD AL,LIPOWSKA-BHALLA G,et al.Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade［J］.Cancer Res,2014,74(19):5458-5468. ［52］ GOLDEN EB,DEMARIA S,SCHIFF PB,et al.An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer［J］.Cancer Immunol Res,2013,1(6):365-372. ［53］ XAVIER GM,VALDERRAMA BP,MEDINA A,et al.Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy(RT)in patients(pts)with localized muscle invasive bladder cancer(MIBC)treated with a selective bladder preservation approach:IMMUNOPRESERVE-SOGUG trial［J］.J Clin Oncol,2021,39(15):4505. ［54］ BALAR AV,MILOWSKY MI,O' DONNELL PH,et al.Pembrolizumab(pembro)in combination with gemcitabine(gem)and concurrent hypofractionated radiation therapy(RT)as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder(MIBC):A multicenter phase 2 trial［J］.J Clin Oncol,2021,39(15):4504. ［55］ GALSKY MD,DANESHMAND S,CHAN KG,et al.Phase 2 trial of gemcitabine,cisplatin,plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer(MIBC):HCRN GU 16-257［J］.J Clin Oncol,2021,39(15):4503-4503. ［56］ ODDENS J,BRAUSI M,SYLVESTER R,et al.Final results of an EORTC-GU cancers group randomized study of maintenance bacillus calmette-guérin in intermediate-and high-risk Ta,T1 papillary carcinoma of the urinary bladder:one-third dose versus full dose and 1 year versus 3 years of maintenance［J］.Eur Urol,2013,63(3):462-472. ［57］ FUKUMOTO K,KIKUCHI E,MIKAMI S,et al.Clinical role of programmed cell death-1 expression in patients with non-muscle-invasive bladder cancer recurring after initial bacillus calmette-guérin therapy［J］.Ann Surg Oncol,2018,25(8):2484-2491. ［58］ BALAR AV,KAMAT AM,KULKARNI GS,et al.Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG(KEYNOTE-057):An open-label,single-arm,multicentre,phase 2 study［J］.Lancet Oncol,2021,22(7):919-930. ［59］ BLACK PC,TANGE C,SINGH P,et al.Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer:SWOG S1605(NCT# 02844816)［J］.Journal of Clinical Oncology,2020,38(15):5022. ［60］ BLACKPC,TNGEN C,SINGH P,et al.Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer:SWOG S1605(NCT# 02844816)［J］.Journal of Clinical Oncology,2021,39(15):4541. ［61］ FARIN MS,LUNDGRE KT,BELLMUNT J.Immunotherapy in urothelial cancer:Recent results and future perspectives［J］.Drugs,2017,77(10):1077-1089.

Memo

Memo:
复旦大学教育部/卫健委/医科院医学分子病毒学重点实验室2021年度开放课题（编号：FDMV-2021004）
Last Update: 1900-01-01